KaydedilenlerDerginizi ekleyin

Dergiler / Annals of Medical Research / 2019 / Cilt: 26 - Sayı: 10

The association of urotensin II with arterial stiffness and atherosclerosis in patients with autosomal dominant polycystic kidney disease

Emre ASILTÜRK
Melahat ÇOBAN
Süleyman DOLU
Bekir EROL
Hamit Yaşar ELLİDAĞ
Yıldız KILAR SÖZER
Sayfa
2437–2443
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

There was no relationship between UT II and AS and atherosclerosis.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aim: Cardiovascular events are associated with increased mortality in patients with autosomal dominant polycystic kidney disease(ADPKD).
📊
Temel Bulgular & Veri:The aim of the study was to investigate the relationshipbetween UT II and arterial stiffness (AS) and atherosclerosis in ADPKD patients.Material and Methods: This cross-sectional study was conducted on 55 ADPKD patients with a mean age of 50 ± 14.4years.
💡
Sonuç & Katkı:There was no relationship between UT II and AS and atherosclerosis.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Aim: Cardiovascular events are associated with increased mortality in patients with autosomal dominant polycystic kidney disease(ADPKD). Urotensin II (UT II) is the most potent vasoconstrictor peptide. The aim of the study was to investigate the relationshipbetween UT II and arterial stiffness (AS) and atherosclerosis in ADPKD patients.Material and Methods: This cross-sectional study was conducted on 55 ADPKD patients with a mean age of 50 ± 14.4years. Thepresence of AS was determined with brachial-ankle pulse wave velocity (baPWV) and the presence of atherosclerosis was determinedwith carotid artery intima-media thickness (CA-IMT). Plasma UT II levels were determined by enzyme-linked immunosorbent assay.Results: Mean log10 UT II was 0.92±0.16 ng/mL. Mean baPWV and CA-IMT were 7.65±1.5 m/sec and 0.63±0.13 mm, respectively.Log10 UT II (p=0.009), baPWV (p < 0.001) and CA-IMT (p=0.001) were high in patients compared to healthy individuals. There was anindependent relationship between log10 UT II and creatinine (p=0.044) and spot urine protein-creatinine ratio (UPCR) (p=0.026) inmultiple regression analysis. There was no relationship between log10 UT II and baPWV and CA-IMT.Conclusion: High plasma UT II levels were observed in ADPKD patients compared to healthy individuals. There was a relationshipbetween UT II and kidney dysfunction and proteinuria. There was no relationship between UT II and AS and atherosclerosis.

🔖

Bu Makaleye Atıf Yap

ASILTÜRK, E., ÇOBAN, M., DOLU, S., EROL, B., ELLİDAĞ, H. Y., SÖZER, Y. K. (2022). The association of urotensin II with arterial stiffness and atherosclerosis in patients with autosomal dominant polycystic kidney disease. Annals of Medical Research, Cilt: 26 - Sayı: 10, 2437–2443. https://ajindex.com/articles/447022

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Kocaman O, Oflaz H, Yekeler E, et al. Endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2004;43:854-60
  2. Wang D, Iversen J, Wilcox CS, et al. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int 2003;64:1381–8
  3. Townsend RR, Wimmer NJ, Chirinos JA, et al. Aortic PWV in chronic kidney disease. A CRIC ancillary study. Am J Hypertens 2010;23:282–9
  4. Borresen ML, Wang D, Strandgaard S. Pulse wave reflection is amplified in normotensive patients with autosomaldominant polycystic kidney disease and normal renal function. Am J Nephrol 2007;27:240-6
  5. Kocyigit I, Kaya MG, Orscelik O, et al. Early arterial stiffness and inflammatory bio-markers in normotensive polycystic kidney disease patients. Am J Nephrol 2012;36:11-8
  6. Richards AM, Charles C. Urotensin ΙΙ in the cardiovascular system. Peptides 2004;25:1795-802
  7. Wilkinson IB, Affolter JT, de Haas SL, et al. High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc Res 2002;53:341-7
  8. Tsoukas P, Kane E, Giaid A. Potential clinical implications of the urotensin II receptor antagonists. Front Pharmacol 2011;2:38
  9. Song N, Ding W, Chu S, et al. Urotensin II stimulates vascular endothelial growth factor secretion from adventitial fibroblasts in synergy with angiotensin II. Circ J 2012;76:1267-73
  10. Satıroglu O, Durakoglugil ME, Cetin M, et al. The role of urotensin II and atherosclerotic risk factors in patients with slow coronary flow. Interv Med Appl Sci 2016;8:158–63
  11. Totsune K, Takahashi K, Arihara Z, et al. Role of urotensin II in patients on dialysis. Lancet 2001;358:810-1.9
  12. Mallamaci F, Cutrupi S, Pizzini P, et al. Urotensin II in endstage renal disease: an inverse correlate of sympathetic function and cardiac natriuretic peptides. J Nephrol 2005;18:727–32
  13. Matsushita M, Shichiri M, Imai T, et al. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 2001;19:2185–90
  14. Mori N, Hirose T, Nakayama T, et al. Increased expression of urotensin II-related peptide and its receptor in kidney with hypertension or renal failure. Peptides 2009;30:400-8
  15. Ravani P, Tripepi G, Pecchini P, et al. Urotensin II is an inverse predictor of death and fatal cardiovascular events in chronic kidney disease. Kid